Current Research

Airway Closure during Extracorporeal membrane oxygenation: The AiCLOSE study

To describe the prevalence of complete airway closure in patients with acute hypoxemic respiratory failure on VV-ECMO and its association with outcome.


Assessment of ECMO in acute myocardial infarction with Non-reversible Cardiogenic shock to Halt Organ failure and Reduce mortality

ANCHOR is a multicenter, randomized, controlled trial. Its primary objective is to determine if early VA-ECMO in conjunction with optimal medical treatment would improve clinical outcomes 30 days following randomization as compared with optimal medical treatment alone in patients with acute myocardial infarction complicated by cardiogenic shock.


Antibiotic, Sedative and Analgesic Pharmacokinetics during Extracorporeal Membrane Oxygenation: a multi-centre study to optimise drug therapy during ECMO

This is a multi-centre, open-label, descriptive pharmacokinetic (PK) study.

BLENDER: Blend to Limit Oxygen in ECMO: A Randomised Controlled Registry Trial

To determine in patients requiring venoarterial (V-A) ECMO, whether the use of a conservative as compared with liberal oxygen strategy, results in a greater number of ICU-free days at day 60.







The International Observational Study on BLood Management for Mechanical Circulatory Support using EXtracorporeal Membrane Oxygenation aims to describe bleeding, thromboembolic complications, blood management and anticoagulation in cardiac ECLS and investigate its associations with morbidity and mortality.

It will identify risk factors for these complications and blood product usage to provide information on current standard of care for future prospective interventional trials.​

The study has started recruitment in late 2019 and centers can express their interest at


PRONECMO: PRONing to Facilitate Weaning From ECMO in Patients With Refractory Acute Respiratory Distress Syndrome

Prone positioning (PP) has been used for more than 30 years in patients with acute hypoxemic respiratory failure and in particular with ARDS. Initially, PP in ARDS patients was proposed as an efficient mean to improve oxygenation, sometimes dramatically, in a large number of patients. In addition, it is now clear, and data are still accumulating, that PP is also able to prevent VILI which is as important as maintaining safe gas exchange in mechanical ventilation. Therefore, PP is a strategy that covers the two major goals of ventilator support in ARDS patients, maintaining safe oxygenation and preventing VILI and reducing mortality at the end. This latter objective makes sense on ECMO as one of the main objective of this device is to markedly reduce VILI by resting the lung.

Considering that PP is a valuable and safe therapy to reduce VILI, its combination with ECMO could enhance VILI prevention. In recent preliminary studies, it was reported that the combination of VV-ECMO and PP was associated with a dramatic improvement in oxygenation, in pulmonary and thoracic compliance and in chest X-ray findings. It may thus facilitate the weaning of ECMO and can be performed without compromising the safety of the patients. Lung recruitment and improvement in ventilation/perfusion mismatch on prone position may both contribute to improve oxygenation. PP may therefore be efficient to hasten the weaning of VV-ECMO when atelectasis and ventilation/perfusion mismatch occur under ultra-protective ventilation even in patients in whom pre-ECMO PP failed. In addition, it could also enhance ventilator induced lung injury prevention on ECMO. 

PRotective vEntilation with veno-venouS lung assisT in respiratory failure

Randomized, allocation concealed, controlled, open, phase 3 pragmatic clinical effectiveness trial to determine whether VV-ECCO2R in mechanically ventilated patients with acute hypoxaemic respiratory failure in intensive care improves mortality at 90 days.



Strategies for Optimal Lung Ventilation in ECMO for ARDS

To assess if a CPAP strategy that minimizes end-tidal pulmonary stress/strain mitigates VILI in comparison to current MV using tidal ventilation in severe ARDS patients on VV ECMO.



A Prospective, Multi-Center, Randomized, Controlled, Pivotal Trial to Validate the Safety and Efficacy of the Hemolung® Respiratory Assist System for COPD Patients Experiencing an Acute Exacerbation Requiring Ventilatory Support

This study is being conducted under an FDA approved IDE to establish the safety and efficacy of an investigational Class III medical device for FDA pre-market approval (PMA) via a pivotal RCT to scientifically validate the indication for its use in acute exacerbation of COPD.  The primary objective is to demonstrate the safety and efficacy of using the Hemolung RAS to provide low-flow ECCO2R as an alternative or adjunct to invasive mechanical ventilation versus standard of care invasive mechanical ventilation alone to increase ventilator-free days for COPD patients who require respiratory support due to an acute exacerbation of their COPD.


Gas eXchange eXtracorporeaL techniques: How many candidates in the ICU?

Prospective, observational study screening patients that meet criteria for ECLS to evaluate the incidence of patients who may be candidates for the different forms of extracorporeal support in ICU.

ECMO Line Survey

The ECMO Line Survey seeks to gain an understanding of the practical bedside aspects of care undertaken nationally and internationally, and identify any differences that exist. This baseline data will assist in developing future research priorities and support the establishment of best practice standards of care.